argenx (ARGX) Stock Price, News & Analysis

Company Overview

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Key Stats

• Today's Range: $578.69 to $595.02
• 50-Day Range: $532.27 to $656.65
• 52-Week Range: $359.37 to $678.21
• Volume: 339,403 shs
• Average Volume: 325,549 shs
• Market Capitalization: $35.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $698.11
• Consensus Rating: Buy

argenx Stock Analysis - MarketRank™

argenx scored higher than 67% of companies evaluated by MarketBeat, and ranked 331st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

argenx has received a consensus rating of Buy. The company's average rating score is 3.04, and is based on 20 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

argenx has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 246.65%

Earnings Growth

Earnings for argenx are expected to grow by 246.65% in the coming year, from $3.13 to $10.85 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of argenx is -658.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of argenx is -658.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

argenx has a P/B Ratio of 8.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.75% of the outstanding shares of argenx have been sold short.

Short Interest Ratio / Days to Cover

argenx has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in argenx has recently increased by 0.88%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

argenx does not currently pay a dividend.

Dividend Growth

argenx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.75% of the outstanding shares of argenx have been sold short.

Short Interest Ratio / Days to Cover

argenx has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in argenx has recently increased by 0.88%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.47

News Sentiment

argenx has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for argenx this week, compared to 10 articles on an average week.

Search Interest

5 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

11 people have added argenx to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, argenx insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.43% of the stock of argenx is held by insiders.

Percentage Held by Institutions

60.32% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARGX Stock Analysis - Frequently Asked Questions

How have ARGX shares performed this year?

argenx's stock was trading at $615.00 at the beginning of 2025. Since then, ARGX stock has decreased by 5.7% and is now trading at $579.77.
View the best growth stocks for 2025 here.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) announced its earnings results on Thursday, May, 8th. The company reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. The company earned $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. argenx had a negative net margin of 2.11% and a negative trailing twelve-month return on equity of 1.45%.
Read the conference call transcript.

When did argenx IPO?

argenx (ARGX) raised $65 million in an initial public offering (IPO) on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

Top institutional investors of argenx include Price T Rowe Associates Inc. MD (8.82%), Wellington Management Group LLP (0.67%), Invesco Ltd. (0.63%) and Lord Abbett & CO. LLC (0.45%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that argenx investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/27/2025
• Next Earnings (Estimated): 7/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARGX
• CIK: 1697862
• Web: www.argenx.com
• Phone: (176) 303-0488
• Fax: N/A
• Employees: 650
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $698.11
• High Stock Price Target: $1,065.00
• Low Stock Price Target: $500.00
• Potential Upside/Downside: +18.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.04
• Research Coverage: 23 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $16.21
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 187.73
• P/E Growth: N/A
• Net Income: $-295,050,000.00
• Net Margins: -2.11%
• Pretax Margin: N/A
• Return on Equity: -1.45%
• Return on Assets: -1.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.53
• Quick Ratio: 7.88

Sales & Book Value

• Annual Sales: $2.58 billion
• Price / Sales: 13.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $69.22 per share
• Price / Book: 8.49

Miscellaneous

• Outstanding Shares: 61,060,000
• Free Float: 59,285,000
• Market Cap: $35.88 billion
• Optionable: Optionable
• Beta: 0.57